Drugs / LTB-SA7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06719219 | Jan 2025 → Mar 2026 | staphylococcus aureus infection | LimmaTech Biologics AG | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LTB-SA7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06719219 ↗ |
| Modality | Vaccine | “LTB-SA7 is a candidate vaccine designed to induce immune response against toxins produced by Staphylococcus aureus.” NCT06719219 ↗ |